Here are the DEF 14A proxy statements from Waters Corp (WAT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow WAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WAT filings page.
Waters Corporation is soliciting votes for its 2026 annual shareholder meeting and highlighting strong 2025 performance and a transformative acquisition. The company closed the purchase of BD’s Biosciences & Diagnostic Solutions businesses, aiming to build a differentiated global life sciences and diagnostics leader.
For 2025, full-year sales grew 7% on both reported and constant-currency bases, recurring revenue rose 8%, and adjusted earnings per share increased 11% to $13.13. Waters reports a 54% five-year total shareholder return and TSR ahead of major life science tools peers since mid-2020. Executive bonuses under the annual incentive plan paid at 110% of target on corporate results, and 2023 performance stock units paid at 65% of target.
Shareholders are asked to elect 11 directors, ratify PricewaterhouseCoopers as auditor for 2026, and approve on an advisory basis executive compensation. Governance topics include majority voting for directors, proxy access, enhanced stock ownership guidelines (CEO at six times salary, other NEOs at three times), cybersecurity and risk oversight, and an 82% favorable 2025 Say-on-Pay vote.